A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs.
about
The development of associate learning in school age childrenMisuse of Prescription Opioid Medication among Women: A Scoping ReviewBridging the gap between education and appropriate use of benzodiazepines in psychiatric clinical practiceDissociative seizures: a challenge for neurologists and psychotherapistsAssessment of cognitive safety in clinical drug developmentDrugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: A systematic review and meta-analysisAssociation between Benzodiazepine Use and Dementia: Data Mining of Different Medical Databases.Benzodiazepine use and risk of Alzheimer's disease: case-control study.Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review.Assessing neurocognitive function in psychiatric disorders: a roadmap for enhancing consensus.Benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study.Cognitive dysfunction in major depressive disorder: effects on psychosocial functioning and implications for treatment.Depression and employment status in primary and tertiary care settingsInappropriate benzodiazepine use in elderly patients and its reduction.A consumer-targeted, pharmacist-led, educational intervention to reduce inappropriate medication use in community older adults (D-PRESCRIBE trial): study protocol for a cluster randomized controlled trialConcordance Between Anticholinergic Burden ScalesA correlativity study of plasma APL1β28 and clusterin levels with MMSE/MoCA/CASI in aMCI patients.Use of the EMPOWER brochure to deprescribe sedative-hypnotic drugs in older adults with mild cognitive impairment.An educational intervention to reduce the use of potentially inappropriate medications among older adults (EMPOWER study): protocol for a cluster randomized trial.Attitudes Toward Use of Benzodiazepines among U.S. Hospice Clinicians: Survey and Review of the LiteratureAssociation Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older AdultsManaging insomnia: an overview of insomnia and pharmacologic treatment strategies in use and on the horizon.Potentially Inappropriate Medication in Community-Dwelling Primary Care Patients who were Screened Positive for Dementia.Educational needs, practice patterns and quality indicators to improve geriatric pharmacy care.Instrumented Trail-Making Task to Differentiate Persons with No Cognitive Impairment, Amnestic Mild Cognitive Impairment, and Alzheimer Disease: A Proof of Concept Study.National Trends in Antidepressant, Benzodiazepine, and Other Sedative-Hypnotic Treatment of Older Adults in Psychiatric and Primary Care.No End in Sight: Benzodiazepine Use in Older Adults in the United States.Anticholinergic drugs and functional, cognitive impairment and behavioral disturbances in patients from a memory clinic with subjective cognitive decline or neurocognitive disorders.Correcting miR92a-vGAT-Mediated GABAergic Dysfunctions Rescues Human Tau-Induced Anxiety in Mice.Psychotropic drugs and CYP2D6 in late-life psychiatric and neurological disorders. What do we know?Sequential drug treatment algorithm for agitation and aggression in Alzheimer's and mixed dementia.Management of older adults with dementia who present to emergency services with neuropsychiatric symptoms.Learning and memory in the forced swimming test: effects of antidepressants having varying degrees of anticholinergic activity.Benzodiazepine Use in Older Adults in the United States, Ontario, and Australia from 2010 to 2016.An interdisciplinary memory clinic: a novel practice setting for pharmacists in primary care.Association of the Centers for Medicare & Medicaid Services' National Partnership to Improve Dementia Care With the Use of Antipsychotics and Other Psychotropics in Long-term Care in the United States From 2009 to 2014.Anticholinergic drugs and risk of dementia: case-control study.Prescription Benzodiazepine Use Among Older Adults: A Critical ReviewQ58775162Optimizing medications in older adults with cognitive impairment: Considerations for primary care clinicians
P2860
Q21131993-9D53A6C0-C1AD-45E9-A57E-05FE54BFDBCFQ26738473-F1D6582E-7DC3-4307-BE08-BA693A6847CAQ26800235-7C423EA3-4657-4374-A074-0CE7B3839B3DQ27024353-ACD8443D-87DC-4DB7-8B72-8D92D9ECD1B0Q28084637-AF65648D-FE68-4A84-9F8B-8480B9E6B903Q28258219-09696ACC-6A4A-4AE2-8B82-7C1BABAB38ABQ31144205-EC2C9C95-715E-4C9F-AF85-525F728ED2C2Q34157456-BA45CC82-948B-43AF-AB40-A0597591C8E3Q34429787-23B6B719-D353-47C9-B94A-59D9145F648FQ34603013-B9ED5FF1-36BE-477A-910C-2CC0A425273FQ34675556-16A8D9EA-EE8C-43B5-86D8-3B1B36D1D3DDQ35006371-0302057A-EF28-4703-AF68-368728FD38E4Q35038743-845AEA60-7181-4DCD-9061-54D1A53B5159Q35536890-1054BB5C-84CB-4AB3-BADA-6D8389841CE9Q35881312-65A4213A-909C-4EB5-8A97-6B10C68859C4Q36197055-3D784E12-3F8D-4002-88CB-090D3D165945Q36209423-49744D9F-67B1-41EA-B3BF-B307A1C00796Q36265372-22699536-02D5-46BC-883B-84F464B5FC12Q36752098-ECE052B7-36EB-401B-B99F-FA8C1DBEDE19Q36881978-32AF8CD0-5F57-4A71-86CA-061C38DCCE01Q37268405-54B04E59-78CC-495E-94B5-7BCC778C11D7Q37450164-3C20DD09-37AF-4F91-8089-1D84BF895A1DQ37489285-D103115D-57A9-41B8-8E37-8DDE07A63D98Q37654780-C59EFBBD-DF36-406B-82D8-654F853070DAQ38794466-90C9AB3F-EAE0-4EDC-B0C7-936791BE64A6Q38816967-C40BEFE4-A160-49AC-AD12-5DF37C6460D0Q39158839-02A0C876-CB3F-4A97-9FCC-D3B8A8C72BA8Q41214474-3167073A-4DD6-4589-A0AC-DF977C9F92DFQ47349501-04BCA97E-B875-4D8D-89C0-FCAF8987A231Q47450129-C45689F3-2828-4670-9909-E95B0B600BA0Q47555313-5D1FDE37-5F45-46C5-8F04-AA1E9FB44DE0Q48039873-E30BC1CA-43C2-43E0-9ACA-B71D66430C11Q48059396-C59E1E97-71A9-42A0-8078-067B3B5B4583Q50048144-034D7AB9-7F5D-4A0E-B4A4-430ED619F360Q50856472-FCB7EE65-1D35-4BAC-8CCB-E978CA84CA17Q51762075-6DC496FA-4EBA-4345-9BD6-4EE04DAF522CQ55037888-27478A36-05ED-4EB4-885F-8DFC77BB9EFCQ57163945-C79BAD0F-25B5-4111-8337-70035687451AQ58775162-E1B1A743-7781-4B30-962B-5138CBE04151Q58775224-E8B678FE-9317-44B9-850F-382806186CB1
P2860
A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
A systematic review of amnesti ...... e, GABAergic and opioid drugs.
@en
type
label
A systematic review of amnesti ...... e, GABAergic and opioid drugs.
@en
prefLabel
A systematic review of amnesti ...... e, GABAergic and opioid drugs.
@en
P2093
P2860
P1433
P1476
A systematic review of amnesti ...... e, GABAergic and opioid drugs.
@en
P2093
Amélie Paquette
Cara Tannenbaum
Jayna Holroyd-Leduc
Sarah Hilmer
P2860
P304
P356
10.2165/11633250-000000000-00000
P577
2012-08-01T00:00:00Z
P6179
1069132371